Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash and investments of $301.8 million, indicating a strong financial position to support ongoing clinical programs [23] - The funds expended in 2025 were primarily directed towards the advancement of the HCV Phase III program and discovery efforts for HEV [23] - R&D expenses increased in 2025 compared to 2024, driven by external spending for HCV clinical development, while G&A expenses decreased due to lower stock-based compensation [24] Business Line Data and Key Metrics Changes - The global Phase III HCV program is on track, with enrollment completed for the North American trial C-BEYOND and expected completion for C-FORWARD by midyear [7][12] - The company anticipates top-line results for C-BEYOND by midyear and for C-FORWARD by year-end [7][26] - The HEV program is positioned as a strategic expansion, with AT-587 selected as the lead product candidate, aiming to address a significant unmet need in immunocompromised patients [20][21] Market Data and Key Metrics Changes - In the U.S., approximately 160,000 new chronic HCV infections are reported annually, with only 85,000 patients treated, highlighting a significant treatment gap [8][16] - The incidence of chronic Hepatitis C infections in the U.S. has nearly doubled from 2.5 million in 2015 to approximately 4 million today [8] - The unmet need for HEV treatment represents a market opportunity estimated between $750 million and $1 billion per year [20] Company Strategy and Development Direction - The company is focused on delivering a differentiated and optimized therapy for HCV, with a regimen designed to fit into the test and treat model of care [5][26] - The commercial strategy includes a user-friendly blister card for adherence and a projected profitability shortly post-launch [17] - The HEV program represents a strategic expansion of the antiviral pipeline, addressing a major unmet need for patients with chronic HEV [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving enrollment targets for both C-BEYOND and C-FORWARD, indicating a robust clinical development strategy [29] - The company anticipates a pivotal year in 2026, with key milestones expected from both the HCV and HEV programs [26] - Management highlighted the importance of the treatment duration and the regimen's profile in influencing prescriber preferences and market uptake [41] Other Important Information - The company returned $25 million to stockholders through a share repurchase program in 2025, reflecting a commitment to shareholder value [24] - The company is preparing for a commercial launch of its HCV product, with a focus on a concentrated prescriber base [17] Q&A Session Summary Question: Does achieving enrollment targets for C-BEYOND increase confidence in C-FORWARD? - Management confirmed that cirrhotic enrollment has not been an issue and they expect to achieve overall targets for both trials [29] Question: Can you discuss the commercial landscape and pricing evolution for HCV? - Management indicated that the distribution market is well understood, and preliminary research shows payers are interested in including the new regimen in formularies [33][34] Question: How does the primary endpoint analysis for C-BEYOND affect the regimen's effect size? - Management noted that the modified intent-to-treat analysis allows for flexibility in dosing, which could enhance the regimen's perceived efficacy [37][38]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash and investments of $301.8 million, indicating a strong financial position to support ongoing clinical programs [24] - The funds expended in 2025 were primarily directed towards the advancement of the HCV Phase 3 program and discovery efforts for HEV treatment [24] - R&D expenses increased in 2025 compared to 2024, driven by external spending on the HCV Phase 3 clinical development [25] Business Line Data and Key Metrics Changes - The global Phase 3 HCV program is on track, with enrollment completed for the North American trial, C-BEYOND, involving over 880 patients [6] - The company anticipates top-line results for C-BEYOND by mid-year and for C-FORWARD by year-end [6][27] - The HEV program has been initiated with AT-587 as the lead product candidate, with plans to start a first-in-human study mid-year [6][27] Market Data and Key Metrics Changes - The incidence of new chronic Hepatitis C infections in the U.S. has increased to approximately 4 million, with only 85,000 patients treated annually [8] - The market opportunity for chronic HEV treatment is estimated to be between $750 million and $1 billion per year, addressing a significant unmet need [20] Company Strategy and Development Direction - The company aims to deliver top-line Phase 3 results for HCV treatments that feature high efficacy, short treatment duration, and low risk of drug-drug interactions [27] - The HEV program represents a strategic expansion of the antiviral pipeline, targeting a vulnerable patient population with no approved treatments available [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving enrollment targets for both C-BEYOND and C-FORWARD trials, indicating a robust clinical development strategy [30] - The company is focused on maintaining financial discipline while advancing its HCV and HEV product candidates, projecting a cash runway extending through 2027 [25][26] Other Important Information - The company returned $25 million to stockholders through a share repurchase program in 2025, reflecting a commitment to drive value for stockholders [24] - The commercial package for HCV will include a blister card for convenience and adherence, with a simple 4-week dosing regimen [17] Q&A Session Summary Question: Does achieving enrollment targets for the cirrhotic population for C-BEYOND increase confidence in C-FORWARD? - Management confirmed that they are on track to achieve overall targets for both trials, with cirrhotic enrollment not being an issue [30] Question: Can you discuss the commercial landscape and pricing evolution for HCV treatments? - Management indicated that the specialty market for DAA is well understood, with stable pricing trends and positive interest from payers regarding the new regimen [34][35] Question: How does the primary endpoint analysis for C-BEYOND affect the potential market uptake? - Management noted that the modified intent-to-treat analysis allows for flexibility in dosing, and the positive profile of the regimen is expected to resonate well with prescribers [39][40]

Core Insights - Atea Pharmaceuticals has initiated the global Phase 3 C-FORWARD trial for the combination regimen of bemnifosbuvir and ruzasvir to treat hepatitis C virus (HCV) [1][2] - The regimen is designed to be a potential best-in-class treatment with a short duration of 8 to 12 weeks and low risk for drug-drug interactions [1][3] - HCV remains a significant global health issue, with approximately 50 million people infected worldwide, including 2.4 to 4 million in the US [2][9] Group 1: Trial Details - The C-FORWARD trial is the second Phase 3 trial, complementing the C-BEYOND trial currently enrolling patients in the US and Canada [1][5] - Each Phase 3 trial aims to enroll around 880 treatment-naïve patients, comparing the fixed-dose combination of bemnifosbuvir and ruzasvir to sofosbuvir and velpatasvir [5] - The primary endpoint for both trials is achieving HCV RNA below the lower limit of quantitation (LLOQ) at 24 weeks, indicating sustained virologic response (SVR12) [6] Group 2: Efficacy and Safety - Results from a Phase 2 study showed a robust 98% SVR12 rate in the treatment-adherent population and 95% in the efficacy evaluable population [7] - Additional Phase 1 studies indicated a low risk of drug-drug interactions and safety in patients co-infected with HIV [8] - Bemnifosbuvir has demonstrated significantly higher potency compared to sofosbuvir, with a 10-fold increase in activity against various HCV genotypes [11] Group 3: Market Context - The evolving patient population for HCV treatment includes many individuals with co-morbidities and complex medical histories, necessitating more accessible treatment options [3] - The current landscape shows a rising burden of untreated HCV, particularly in Europe, mirroring trends in North America [3] - Atea's regimen is positioned to address these challenges by combining high efficacy, short treatment duration, and minimal drug interaction risks [3]

Core Insights - Atea Pharmaceuticals is advancing its Phase 3 clinical trials for the combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), with ongoing patient enrollment in the C-BEYOND trial in the US and Canada, and plans to initiate the C-FORWARD trial globally [4][11][12] - The company reported promising Phase 2 results, indicating a high sustained virologic response (SVR12) rate of 98% among treatment-adherent patients and 95% overall, showcasing the regimen's potential as a best-in-class treatment for HCV [7][11] - Atea's financial results for Q1 2025 show a decrease in research and development expenses to $29.6 million, down from $57.6 million in Q1 2024, attributed to the completion of a previous COVID-19 trial and a focus on HCV development [16][20] Company Updates - Atea is hosting a virtual key opinion leader (KOL) investor event on May 14, 2025, to discuss HCV treatment challenges and the potential of its drug regimen, replacing the traditional earnings call for Q1 2025 [5][6] - The company has engaged Evercore to explore strategic alternatives to enhance shareholder value, including potential partnerships or acquisitions, while also reducing its workforce by approximately 25% to save around $15 million through 2027 [14][15] Financial Performance - As of March 31, 2025, Atea reported cash, cash equivalents, and marketable securities totaling $425.4 million, a decrease from $454.7 million at the end of 2024 [15][22] - The net loss for Q1 2025 was $34.3 million, compared to a net loss of $63.2 million in Q1 2024, reflecting improved operational efficiency [20][22] Clinical Development - The Phase 3 program includes two trials, C-BEYOND and C-FORWARD, each aiming to enroll approximately 880 treatment-naïve patients, comparing the BEM/RZR regimen to the standard sofosbuvir and velpatasvir regimen [11][12] - The primary endpoint for both trials is achieving HCV RNA levels below the lower limit of quantitation at 24 weeks, ensuring consistent evaluation across patient groups [12][13]

Financial Data and Key Metrics Changes - In 2024, R&D expenses declined quarter over quarter but increased year over year, primarily due to higher external spending related to the COVID-19 phase three Sunrise-3 trial and the phase two HCV trial [34] - Interest income decreased quarter over quarter and year over year due to lower investment balances [35] - As of December 31, 2024, the company had $454.7 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2028 [11][36] Business Line Data and Key Metrics Changes - The global phase two trial for the HCV program demonstrated a 98% cure rate in the primary efficacy analysis with an eight-week treatment [7] - The regimen of bemnifosbuvir and ruzasvir is expected to disrupt the global HCV market, which approximates $3 billion in annual net sales [8][15] Market Data and Key Metrics Changes - In the United States, there are between 2.4 to 4 million untreated HCV patients, with only approximately 100,000 patients treated out of 160,000 new infections annually [13][14] - Treated patients in the U.S. resulted in approximately $1.5 billion in net sales last year [15] Company Strategy and Development Direction - The company is initiating a global phase three program for the HCV regimen, with enrollment expected to begin next month [10] - The company has retained Evercore to assist in exploring strategic partnerships related to the phase three HCV program [9] - A workforce reduction of approximately 20-25% was announced to enhance efficiency, expected to result in cost savings of approximately $15 million through 2027 [37] Management's Comments on Operating Environment and Future Outlook - Management believes the global phase three HCV program is de-risked with a compelling value proposition based on substantial preclinical and clinical data [39] - The company aims to become the most prescribed treatment for hepatitis C, potentially disrupting a multibillion-dollar market [40] Other Important Information - The company appointed Arthur Kirsch as a new independent director, bringing extensive financial and strategic advisory experience to the board [9][37] Q&A Session Summary Question: Any specific callouts from the FDA meeting regarding phase three trial design? - Management indicated that the FDA is fully aligned with the approach of conducting two open-label phase three trials and did not have substantive comments on the trial conduct [46][47] Question: What can be expected in terms of the scope of the phase two readout later this half? - Additional data regarding efficacy and safety is expected to be presented at EASL in May [49] Question: Estimated number of cirrhotic patients across the two trials? - Management anticipates enrolling just over 10% cirrhotic patients in the trials, with flexibility in adjusting that number based on enrollment [55][58] Question: How does the modeling compare to Epclusa in the non-cirrhotic population? - The model has been developed by Dr. Alan Perelson, and comparisons with other direct-acting antivirals for HCV can be referenced in their publications [60]

Financial Data and Key Metrics Changes - In 2024, R&D expenses declined quarter over quarter but increased year over year, primarily due to higher external spending related to the COVID-19 phase three Sunrise-3 trial and the phase two HCV trial [34] - Interest income decreased quarter over quarter and year over year due to lower investment balances [35] - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities of $454.7 million, projecting a cash runway into 2028 [11][36] Business Line Data and Key Metrics Changes - The company made significant progress in its HCV program, reporting a 98% cure rate in the primary efficacy analysis from a global phase two trial with an eight-week treatment regimen [7][28] - The phase two trial included 275 treatment-naive patients, achieving a 98% SVR12 rate in adherent patients and a 95% rate regardless of adherence [27] Market Data and Key Metrics Changes - The global HCV market is approximately $3 billion in annual net sales, with a significant number of untreated HCV patients in the U.S. estimated between 2.4 to 4 million [8][13] - In the U.S., approximately 100,000 out of 160,000 new infections are treated annually, resulting in about $1.5 billion in net sales from treated patients [15] Company Strategy and Development Direction - The company is initiating a global phase three program for its HCV regimen, expecting enrollment to begin next month, with a focus on becoming a best-in-class hepatitis C treatment [10][39] - The company has retained Evercore to assist in exploring strategic partnerships related to its phase three HCV program and has taken cost-cutting actions to enhance efficiency [9] Management's Comments on Operating Environment and Future Outlook - Management emphasized the ongoing high rate of HCV infections and the need for new differentiated therapies, highlighting the potential for their regimen to address this healthcare issue [12][14] - The company believes its regimen, if approved, could disrupt the global HCV market and become the most prescribed treatment [40] Other Important Information - The company announced a workforce reduction of approximately 20-25% to enhance efficiency, expected to result in cost savings of about $15 million through 2027 [37] - Arthur Kirsch was appointed as a new independent director, bringing extensive financial and strategic advisory experience to the board [9][37] Q&A Session Summary Question: Any specific callouts from the FDA meeting regarding phase three trial design? - Management indicated that the FDA is fully aligned with their approach of conducting two open-label phase three trials and did not have substantive comments on the trial conduct [46][47] Question: What can be expected in terms of the scope of the phase two readout later this half? - Management expects to present additional data regarding efficacy and safety at the EASL conference in May [49] Question: Estimated number of cirrhotic patients across the two trials? - Management anticipates enrolling just over 10% cirrhotic patients in the trials, with flexibility in adjusting this number based on enrollment [55][58] Question: How does the modeling compare to Epclusa in the non-cirrhotic population? - Management referred to the model developed by Dr. Alan Perelson and suggested checking their publications for comparisons with other direct-acting antivirals [60]

Business Highlights - Robust Phase 2 results for bemnifosbuvir and ruzasvir regimen announced in Dec 2024, supporting potential disruption of the ~$3 billion global HCV market[9] - Successful End-of-Phase 2 meeting with FDA conducted in Jan 2025, with Phase 3 enrollment expected to start in April 2025[9] - Decisive cost-cutting actions in Q1 2025 are expected to contribute ~$15 million in savings through 2027[9] - The company anticipates a cash runway into 2028 due to prudent capital allocation[9, 10] HCV Market and Opportunity - The global HCV market represents approximately $3 billion in annual net sales[9, 16, 59] - The US HCV market accounts for roughly $1.5 billion in net sales in 2024[16] - The US market presents a potential opportunity exceeding $20 billion, assuming treatment of 22 million chronically infected HCV patients at $10000 net revenue per patient[16, 17] Clinical Trial Results and Program - Phase 2 study demonstrated high SVR12 rates, with 98% SVR12 in treatment-adherent patients and 95% SVR12 regardless of adherence[33, 34] - In non-cirrhotic treatment-adherent patients, the SVR12 rate was 99% across genotypes, while it was 97% regardless of adherence[38, 39, 41] - Approximately 25% reduction of workforce in Q1 2025 to enhance efficiency[56] Financials - Cash, cash equivalents, and marketable securities totaled $454721 million as of December 31, 2024[52] - Net loss for the year ended December 31, 2024, was $168385 million, compared to $135956 million for the year ended December 31, 2023[49]